ClinicalTrials.Veeva

Menu
C

Cutting Edge Research Group | Oklahoma City, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lurasidone
Brexpiprazole
Dasotraline
Cariprazine
Ziprasidone
Hydrocodone Bitartrate
Divalproex
Lithium
Vilazodone
Balovaptan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 57 total trials

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment d...

Active, not recruiting
Attention Deficit Hyperactivity Disorder
Drug: Guanfacine hydrochloride (TAK-503)
Other: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine
Locations recently updated

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Placebo
Drug: iclepertin

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Enrolling
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: Placebo
Drug: BOTOX

Trial sponsors

Sumitomo Pharma logo
Pfizer logo
Otsuka logo
Forest Laboratories logo
Roche logo
AbbVie logo
Shire logo
Viatris logo
Abbott logo
Purdue Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems